Immupharma PLC ImmuPharma Commences Trading on Stuttgart Exchange
February 28 2013 - 2:02AM
RNS Non-Regulatory
TIDMIMM
Immupharma PLC
28 February 2013
FOR IMMEDIATE RELEASE 28 FEBRUARY 2013
RNS REACH
ImmuPharma PLC
Commences Trading on the Stuttgart Stock Exchange
ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is pleased to
announces that it has been informed by Baader Bank AG that its
shares are now being traded on the third segment of the Stuttgart
Stock Exchange.
Baader Bank AG has experience and expertise for trading in
German and non-German securities at Germany's leading stock
exchanges in Frankfurt, Berlin-Bremen, Munich and Stuttgart. They
currently have more than 9,000 stocks from 56 countries including
Coca-Cola, Citigroup, Sony and Singapore Airlines.
Dimitri Dimitriou, Chief Executive Officer of ImmuPharma
commented: "We are delighted that we have further expanded our
footprint into Europe with our shares now being traded on the
Stuttgart Exchange. This should help dovetail efforts with our
similar open market listing 'Tradegate' on the Berlin Exchange and
we are confident that through these secondary European listings
they will help support our UK Listing and assist in continuing to
extend and strengthen our investor base."
Ends
For further information please contact:
ImmuPharma plc + 44 (0) 20 7152 4080
Dimitri Dimitriou, Chief Executive
Officer
Dr Robert Zimmer, President and Chief
Scientific Officer
Richard Warr, Chairman
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD & Broker +44 (0) 20 7459 3600
Fred Walsh
Hannah Woodley
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high
sales potential in specialist markets with serious unmet need.
ImmuPharma has five drug candidates in development, two platform
technologies and approximately 70 patents. The Company's most
advanced drug candidate, Lupuzor(TM) a potential blockbuster drug
for Lupus, a chronic autoimmune disease has recently received the
approval from the US FDA to enter phase III with a Special Protocol
Assessment and "Fast Track" designation. The Company's second
potential blockbuster compound in cancer "IPP-204106" is completing
a new Phase I/ II clinical trial with the next generation of
"polyplexed Nucant". ImmuPharma was founded and is led by a
commercially focused Board and management team with extensive
experience. For more information on ImmuPharma please go to:
www.immupharma.com.
About Baader Bank:
Baader Bank is one of Germany's leading investment banks and the
market leader in trading of financial instruments. In investment
banking, it develops financing solutions for companies in
German-speaking countries. The bank offers institutional investors
comprehensive services in marketing and trading of equities, bonds,
and derivatives. As a market maker/specialist, Baader Bank is
responsible for pricing more than 700,000 exchange-traded and OTC
securities. For more information on Baader Bank please go to:
www.baaderbank.de
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFLAFEIDFIV
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024